Development of lipophilic cations as therapies for disorders due to mitochondrial dysfunction

Expert Opinion on Biological Therapy

Volumn 1, Issue 5, 2001, Pages 753-764

  Murphy, Michael P ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Anti oxidants; Degenerative diseases; Friedreich's ataxia; Lipophilic cations; Mitochondria; Mitochondrial diseases

Indexed keywords

CATION; LIPID; METHYLTRIPHENYLPHOSPHONIUM; TRITYL DERIVATIVE;

ANIMAL; ANTIBODY SPECIFICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; METABOLISM; METHODOLOGY; PHARMACEUTICS; REVIEW; SYNTHESIS;

ANIMAL; CATIONS; HUMAN; LIPIDS; MITOCHONDRIAL DISEASES; ONIUM COMPOUNDS; ORGAN SPECIFICITY; TECHNOLOGY, PHARMACEUTICAL; TRITYL COMPOUNDS;

EID: 0035460705     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.5.753     Document Type: Article

References (162)

1. NICHOLLS DG, FERGUSON SJ: Bioenergetics 2. Academic Press, London (1992). • The standard textbook on mitochondrial bioencrgctics.
2. TYLER D: The Mitochondrion in Health and Disease. VCH, New York (1992). • An introduction to mitochondrial biology.
3. SCHEFFLER IE: Mitochondria. Wiley-Liss, New York (1999). • An excellent introduction to all aspects of mitochondria.
4. Mitochondria: DNA, proteins and disease. Darley-Usmer V, Schapira AHV (Eds.) Portland Press, London (1994).
5. ERNSTER L, LUFT R.ORRENIUSS: Mitochondrial diseases. Biochim. Biophys. Acta (1995) 1271:1-292. • An issue devoted to mitochondrial diseases.
6. SCHON EA: Mitochondrial genetics and disease. 7755(2000) 25:555-560. • A good review of mtDNA diseases.
7. NICOTERARBELLOMOG.ORRENIUS S: Calcium-mediated mechanisms in chemically induced cell death. Ann. Rev. Phamacol ToxicoL (1992)32:449-470.
8. BOSSO,MUZZINP,GIACOBINOJ-P: The uncoupling proteins, a review. Euro. J. Endocrinol (1998) 139:1-9.
9. GREEN DR, REED Jû Mitochondria and apoptosis. Science (1998) 281:1309-1312.
10. NICHOLLS DG, BUDD SU Mitochondria and neuronal survival. PhysioL Rtv. (2000) 80:316-360.
11. NISHIKAWAT, EDELSTEIN D, DU XL et al: Normalizing mitochondrial Superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 404:787-790.
12. LUFT R, IKKOS D, PALMIERl G, AL E: A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory chain control. A correlated clinical, biochemical and morphological study.J. Clin. Invest. (1962) 41:1776-.
13. LUFT R: The development of mitochondrial medicine. Proc. Nail Acad. Sei. USA (1994) 91:8731-8738.
14. SMEITINKLVANDENHEUVELL, DIMAURO S: The genetics and pathology of oxidativc phosphorylation. Nature Rev. Genet. (2001) 2:342-352. •• An excellent review of mitochondrial diseases.
15. SCHÖLTE HR: The biochemical basis of mitochondrial diseases.J. Bioenerget. Biomembr. (1988)20:161-191.
16. CHINNERY PF, AL E: Epidemiology of pathogenic mitochondrial DNA diseases. Ann. Neural (2000) 48:188-193.
17. LEONARD JV.SCHAPIRA AH: Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet (2000) 355:299-304.
18. WALLACE DG Mitochondrial diseases in man and mouse. Science (1999) 283:1482-1488.
19. ATTIMONELLIM.ALTAMURAN, BENNE R et al: MitBASE : a comprehensive and integrated mitochondrial DNA database. The present status. Nucleic Acids Res. (2000) 28:148-152.
20. ANDERSON S, BANKIER AT, BARRELL BG et ai: Sequence and organization of the human mitochondrial genome. Nature (1981) 290:457-465. • A classic paper reporting the human mitochondrial DNA sequence.
21. HOLT IJ, HARDING AE, MORGAN-HUGHES JA: Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature (1988) 331:717-719. • The first reports (along with [22]) of a pathogenic mtDNA mutation.
22. WALLACE DC, SINGH G, LOTT MT et al: Mitochondrial DNA mutation associated with Lebers hereditary optic neuropathy. Science (1988) 242:1427-1430. • The first reports (along with [21]) of a pathogenic mtDNA mutation.
23. CHINNERYPE TURNBULL DM: Mitochondrial medicine. Q.J. Med. (1997) 90:657-667. •• An excellent review of mitochondrial medicine.
24. CHINNERYPE TURNBULL DM: Mitochondrial DNA mutations in the pathogenesis of human disease. MoL Med. Tràky (2000) 6:425-432. •• A review covering all aspects of mtDNA diseases.
25. ETOK,TSUBAMOTOY,TERAUCHIY etal: Role of NADH shuttle system in glucose-induced activation of mitochondrial metabolism and insulin secretion. Nature (1999) 283:981-985.
26. FISCHEL-GHODSIAN N: Mitochondrial DNA mutations and diabetes: another step toward individualized medicine. Ann. Intern. Med. (2001) 134:777-779.
27. REID FM, VERNHAM GA, JACOBS HT: A novel mitochondrial point mutation in a maternal pedigree with sensorineural deafness. Human Mut. (1994) 3:243-247.
28. RIORDAN-EVA P, HARDING AE: Leber's hereditary optic neuropathy: the clinical relevance of different mitochondrial DNA mutations.J. Med. Genet. (1995) 32:81-87.
29. TAYLORRW.CHINNERYPF, TURNBULL DM, LIGHTOWLERS RN: Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleotide acids. Nature Genet. (1997) 15:212-215.
30. ROSSIGNOL R, MALGAT M, MAZAT J-P, LETELLIER T: Threshold effect and tissue specificity. Implication for mitochondrial cytopathies. J. BioL Chem. (1999) 274:33426-33432.
31. WALLACE DC: Mitochondrial DNA variation in human evolution, degenerative disease and aging. Am. J. Hum. Genet. (1995) 57:201-223.
32. RICHTER C, PARK J-W, AMES BN: Normal oxidativc damage to mitochondrial and nuclear DNA is extensive, froc. NatL Acad. Sei. USA (1988) 85:6465-6467. • The first report that mtDNA is more oxidatively damaged than nuclear DNA.
33. LARSSON N-G, CLAYTON DA: Molecular genetic aspects of human mitochondrial disorders. Annu. Rev. Genet. (1995)29:151-178.
34. MICHIKAWA Y, MAZZUCCHELLI F, BRESOLIN N, SCARLATO G, ATTARDI G: Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science (1999) 286:774-779. • An important study that showed the accumulation of mitochondrial DNA mutations with age, although the functional consequences of the mtDNA mutations were uncertain.
35. CORRAL-DEBRINSKIM, HORTON T, LOTT MT, SHOFFNER JM, BEAL MF, WALLACE DC: Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nature Genet. (1992) 2:324-329.
36. PITKANEN S, ROBINSON BH: Mitochondrial complex I deficiency leads to increased production of Superoxide radicals and induction of Superoxide dismutasc. J.Clin. Invest. (1996) 98:345-351. • A demonstration that mtDNA mutations may lead to increased mitochondrial radical production.
37. PORTEOUS WK, JAMES AM, SHEARD PW ctaL: Bioenergetic consequences of accumulating the common 4,977 bp mitochondrial DNA deletion. EUT. J. Biochem. (1998) 257:192-201.
38. LINNANEAW.MARZUKIS.OZAWAT, TANAKA M: Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet (1989) 1:642-645.
39. ELSONJL, SAMUELS DC, TURNBULL DM, CHINNERY PF: Random intraccllular drift explains the clonal expansion of mitochondrial DNA mutations with age. Am. J. Hum. Genet. (2001) 68:802-806.
40. ATTARDIG: Biogenesis of mitochondria. Ann. Rev. Cell BioL (1988) 4:289-333.
41. SCHATZ G: The protein import system of mitochondria.J. BioL Chem. (1996) 271:31763-31766.
42. KOEHLERCM.LEUENBERGERD, MERCHANT S, RENOLD A, JUNNE T, SCHATZ G: Human deafness dystonia syndrome is a mitochondrial disease. Proc. NatlAcad. Sei. USA (1999) 96:2141-2146. • The first mitochondrial disease due to a defect in mitochondrial protein import.
43. BOURGERON T, AL E: Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nature Genet. (1995) 11:144149. • A mitochondrial disease due to a nuclear mutation in a respiratory chain protein.
44. KAUKONENJ.JUSELIUSJK, TIRANTl V etaL: Role of adenine nucleotide translocator in mtDNA maintenance. Science (2000) 289:782-785.
45. PRZYREMBELH: Therapy of mitochondrial disorders.J. Inherit. Metab. Dis. (1987) 10:129-146. • An early review of therapies for mitochondrial disorders, before diseases due to mtDNA mutations were known.
46. LEONARD JV.SCHAPIRA AH: Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet (2000) 355:389-394. •• A review focusing on the role of mitochondrial dysfunction in neurodegenerative diseases.
47. CAMPUZANOV.MONTERMINIL, MOLTO MD etal: Friedrcich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science (1996) 271:1423-1427.
48. KAPLAN J: Friedreich's ataxia is a mitochondrial disorder. Proc. Natl. Acad. Set. USA (1999) 96:10948-10949. • A good review of Friedreich's ataxia.
49. PUCCIO H, KOENIG M: Recent advances in the molecular pathogenesis of Friedreich ataxia. Human Molec. Genet. (2000) 9:887-892.
50. PUCCIO H, SIMON D, COSSEE M et al.: Mouse models for Friedreich ataxia exhibit cardiomopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nature Genetics (2001) 27:181-186. •• An important paper reporting the development of conditional fra taxin 'knockout' mice whose pathology strongly suggests mitochondrial oxidatrve damage as the primary pathological event in the disease.
51. KOUTNIKOVAH.CAMPUZANOV, FOURY F, DOLLE P, CAZZALINI O, KOENIG M: Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nature Genet. (1997) 16:345-351.
52. LODI R, COOPER JM, BRADLEY JL et al.: Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl. Acad. Set. USA (1999) 96:11492-11495. •• An important paper directly measuring a mitochondrial defect in Freidreich's ataxia patients by 31P-NMR. This suggests how future measurements of efficacy of therapies for mitochondrial diseases can be made.
53. CAVALIER L, OUAHCHI K, KAYDEN HJ et al: Ataxia with isolated vitamin E deficiency: heterogeneity of mutations and phenotypic variability in a large number of families. Am. J. Hum. Genet. (1998) 62:301-310.
54. EMONDM.LEPAGEG.VANASSEM, PANDOLFO M: Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology (2000) 55:1752-1753.
55. SCHULZ JB, DEHMER T, SCHOLS L et al.: Oxidativc stress in patients with Fricdreich ataxia. Neurology (2000) 55:1719-1721.
56. SOKOL RJ, TWEDT D, MCKIM JM Jr. et al: Oxidant injury to hepatic mitochondria in patients with Wilsons disease and Bedlington terriers with copper toxicosis. Gastroenterolegy (\994) 107:1788-1798.
57. LUTSENKOS, COOPER MJ: Localization of the Wilson's disease protein product to mitochondria. Proc Natl. Acad. Sa. USA (1998) 95:6004-6009.
58. GUM, COOPER JM, BUTLER P étal: Oxidative-phosphorylation defects in liver of patients with Wilsons disease. Lancet (2000) 356:469-474.
59. BOVERIS A and CADENAS E: Mitochondrial production of Superoxide anions and its relationship to the antimycin insensitive respiration. FEES Lett. (1975) 54:311-314.
60. BECKMAN KB, AMES BN: The free radical theory of aging matures. Phys. Rev. (1998)78:547-581. • A survey of the role of mitochondrial oxidative damage in degenerative diseases anil ageing.
61. RAHA S, ROBINSON BH: Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem. (2000) 25:502-508. • A review of mitochondrial free radical production.
62. RADIR.RODRIGUEZM, CASTRO L, TELLERl R: Inhibition of mitochondrial electron transport by peroxynitrite. Arch. Biochem. Biofhys. (1994) 308:89-95.
63. GEROMEL V, KADHOM N, CEBALOSPICOTI et al.: Superoxide-induced massive apoptosis in cultured skin fibroblasts harboring the neurogenic ataxia retinitis pigmentosa (NARP) mutation in the ATPase-6 gene of the mitochondrial DNA. Hum. Mol Genet. (2001) 10:1221-1228.
64. CHANCE B.SIESH, BOVERIS A: Hydroperoxide metabolism in mammalian organs. PhysioL Rev. (1979) 59:527-605. •• One of the first detailed studies on mitochondrial radical production.
65. BOVERIS A: Determination of the production of Superoxide radicals and hydrogen peroxide in mitochondria. Methods EnzymoL (1984) 105:429-435.
66. LI Y, HUANG T-T, CARLSON EJ et al.: Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese Superoxide dismutase. Nature Genet. (1995) 11:376-381.
67. LEBOVTTZRM, ZHANG H, VOGEL H et al.: Neurodegeneration, myocardial injury and perinatal death in mitochondrial Superoxide dismutase-deficient mice. Proc. NatLAcad. Sei. USA (1996) 93:9782-9787.
68. REED D: Glutathione: toxicological implications. Ann. Rfv. Pharmacol. ToxicoL (1990) 30:603-631.
69. COYLE JT, PUTTFARCKEN P: Oxidative stress, glutamate and ncurodegenerative disorders. Science (1993) 262:689-694.
70. 2+ and cell death. Ann. NYAcad. Set. (1992) 648:17-27.
71. SCHAPIRAAHV, COOPER JM, DEXTER D, CLARK JB, JENER P, MARSDEN CD: Mitochondrial complex 1 deficiency in Parkinsons disease.J. Nfurochem. (1990) 54:823-827.
72. COOPER JM, MANN VM, KRIGED, SCHAPIRAAHV: Human mitochondrial complex 1 dysfunction. Biochimica et BiophysicaActa (1992) 1101:198-203. • A review of complex I damage in Parkinson's disease.
73. JENNER P: Altered mitochondrial function, iron metabolism and glutathione levels in Parkinsons disease. Acta Neural. Scand. Suffi. (1993) 146:6-13.
74. LODI R, SCHAPIRA AH, MANNERS D et al: Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neural (2000) 48:72-76.
75. TABRIZISJ, WORKMAN J, HART PE et al: Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. NturoL (2000) 47:80-86.
76. SHIGENAGA MK, HAGEN TM, AMES BN: Oxidative damage and mitochondrial decay in aging. Proc. NatL Acad. Set. USA (1994)91:19771-19778.
77. BEAL MF: Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neural. (1992) 31:119-130.
78. PRICE DL, SISODIA SS, BORCHELT DR: Genetic neurodegenerative diseases: the human illness and transgenic models. Science (1998) 282:1079-1083.
79. SHOULSON I: Experimental therapeutics of neurodegenerative disorders: unmet needs. Science (1998) 282:1072-1074.
80. FINKEL T, HOLBROOK NJ: Oxidants, Oxidative stress and the biology of ageing. Nature (2000) 408:239-247. • A good starting point for the role of Oxidative damage in ageing.
81. MORGAN-HUCHES JA: Mitochondrial diseases. In: Myology. (Edition 2). Engel AG, Franiini-Armsrong C (Eds.), Volume 2 (1992):1610-1660.
82. WALKER UA.BYRNEE: The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Acta Neural. Scand. (1995) 92:273-280.
83. DIMAUROS.HIRANOM, SCHON EA: Mitochondrial encephalomyopathies: therapeutic approaches. NcuroL Sei. (2000) 21:5901-908.
84. SCHAPIRA AH: Mitochondrial disorders. Curr. Of in. Neurol (2000) 13:527-532. • A clinically-oriented review of mitochondrial disorders.
85. TAYLORRW.CHINNERYPF, CLARK KM, LIGHTOWLERS RN, TURNBULL DM: Treatment of mitochondrial disease.J. Biocnerg. Biomembr. (1997) 29:195-205. • An excellent survey of therapies used to date for mitochondrial medicine.
86. VLADUTIU GD: Advances in the genetic mechanisms of mitochondrial disease. Curr. Of in. NeuroL (1997) 10:512-518.
87. WALKER UA, COLLINS S, BYRNE E: Respiratory chain encephalomyopathies: a diagnostic classification. Eur. NeuroL (1996) 36:260-267.
88. VAN BEEKVELT MC, VAN ENGELEN BG, WEVERS RA, COLIER WN: Quantitative near-infrared spectroscopy discriminates between mitochondrial myopathies and normal muscle. Ann. NeuroL (1999) 46:667-670.
89. CHINNERYPF, TURNBULL DM: Clinical features, investigation and management of patients with defects of mitochondrial DNA.J. NeuroL Neurosurg. Psychiatry (1997) 63:559-563.
90. TARNOPOLSKYMA, ROYBD, MACDONALD JR: A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve (1997) 20:1502-1509.
91. KLOPSTOCKT, QUERNER V, SCHMIDT F, GEKELER F et al: A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology (2000) 55:1748-1751.
92. HARPEYJP, CHARPENTIER C, COUDE M: Methylene-blue for riboflavinunresponsive glutaricaciduria Type II. Lancet (1986) 1:391.
93. ELEFFS, KENNAWAYNG, BUISTNR et al: 31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle. Proc. NatL Acad. Set. USA (1984) 81:35293533. • One of the first attempts at a rational therapy for mitochondrial diseases.
94. SCHÖLTE HR, BUSCH HFM, BAKKER HD, BOGAARDJM, LUYT-HOUWEN IEM, KUYT LP: Riboflavin-responsive complex I deficiency. Biochim. Biophys. Acta (1995) 1271:75-83.
95. HAGENTM, WEHR CM, AMES BN: Mitochondrial decay in aging. Ann. NY Acad. Sei. (1998) 854:215-223.
96. HAGEN TM, AL E: Mitochondrial decay in hepatocytes from old rats. Proc. NatL Acad. Sei. USA (1997) 94:3064-3069.
97. DE STEFANON, MATTHEWS PM, FORD B, GENGEA, KARPATI G, ARNOLD DL: Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology (1995) 45:1193-1198.
98. SUH JH, SHIGENO ET, MORROW JD ctaL: Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)-(alpha)-lipoicacid. FASEBJ. (2001) 15:700-706.
99. HAGENTM, INGERSOLLRT, LYKKESFELDTJ et al: (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage and increased metabolic rate. FASEBJ. (1999) 13:411-418.
100. MIQUELJ, FERRANIZML.DEJUAN E, SEVILLA I, MARTINEZ M: N-acetylcysteine protects against age-related decline of oxidative phosphorylation in liver mitochondria. Eur.J. PharmacoL (1995) 292:333-335.
101. MELOV S, SCHNEIDER JA, DAY BJ et ai: A novel neurological phenotype in mice lacking mitochondrial manganese Superoxide dismutase. Nature Genet. (1998) 18:159-163.
102. SALVEMINI D, WANG Z-Q, ZWEIER JL et al.: A nonpeptidyl mimic of Superoxide dismutase with therapeutic activity in rats. Science (1999) 286:304-306.
103. RONG Y, DOCTROWSR, TOCCO G, BAUDRY M: EUK-134, a synthetic Superoxide dismutase and catalase mimetic, prevents oxidative stress and attenuates kainate-induced neuropathology. Proc. NatL Acad. Sei. USA (1999) 96:9897-9902.
104. BUTTERFIELD DA, HOWARD BJ, YATIN S, ALLEN KL, CARNEYJM: Free radical oxidation of brain proteins in accelerated senesence and its modulation by N-tert-butyl-alpha-phenylnitrone. Proc. NaAAcad. Set. USA (1997) 94:674-678.
105. SOKOL RJ, MCKIM JM, GOFF MC et ai: Vitamin E reduces oxidant injury to mitochondria and the hepatoxicity of taurochenodeoxycholic acid in the rat. Gastrpenterology(1998) 114:164-174.
106. CRANE FL, BARR R: Determination of ubiquinones. Meth. Enzymol. (1971) 18Q137-165.
107. CRANE FL: Hydroquinone dehydrogenases. Ann. Rev. Biochem. (1977) 46:439-469.
108. ERNSTER L, DALLNER G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim, Biophys. Acta (1995) 1271:195-204.
109. INGOLD KU, BOWRY VW, STOCKER R, WALLING C: Autoxidation of lipids and antioxidation by a-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids. Proc. Natl. Acad. Sei. USA (1993) 90:45-49.
110. MAGUIRE JJ, WILSON DS, PACKER L: Mitochondrial electron transport-linked tocopheroxyl radical reduction.J. Biol. Chem. (1989) 264:21462-21465.
111. STOYANOVSKY DA, OSIPOV AN, QUINN PJ, KAGAN VE: Ubiquinone-dependent recycling of vitamin E radicals by Superoxide. Arch. Biochem. Biophys. (1995) 323:343-351.
112. ROTIG A, APPELKVIST EL, GEROMEL V etaL: Quinonc-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet (2000) 356:391-395. • Oneof the few cases, along with [113]. where a simple therapy for a mitochondrial disease works.
113. MUSUMECIO, NAINI A, SLONIM AE et al.: Familial cerebellar ataxia with muscle coenzyme QlO deficiency. Neurology (2001) 56:849-855. • Oneof the few cases, along with [112], where a simple therapy for a mitochondrial disease works.
114. YUZURIHA T, TAKADA M, KATAYAMA K: Transport of [14C]coenzyme QJO from the liver to other tissues after intravenous administration to guinea pigs. Biochim. Biophys. Acta (1983) 759:286-291.
115. 10 administration increases brain mitochondrial concentrations and exerts neurprotective effects. Proc. Natl. Acad. Sei. USA (1998) 95:8892-8897.
116. ROSENFELDT FL, PEPE S, OU R étal: Coenzyme Q10 improves the tolerance of the senescent myocardium to aerobic and ischémie stress: studies in rats and in human atrial tissue. Biofactors (1999) 9:291-299.
117. SHOFFNER JM, LOTT MT, VOLJAVEC AS et al.: Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip replication model and metabolic therapy. Proc. Natl Acad. Sei. USA (1989) 86:7952-7956.
118. BRESOLINN, DORIGUZZI C, PONZETTO C etal: Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J. Neural Sei. (1990) 100:70-78.
119. 10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology (1993) 43:884-890.
120. PETERSON PL: The treatment of mitochondrial myopathies and encephalomyopathies. Biochim. Biophys. Acu (1995) 1271:275-280.
121. GOLD R, SEIBEL P, REINELT G etal: Phosphorus magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies: results of a 6-month therapy study with coenzyme Q. EUT. Neural (1996) 36:191-196.
122. OZAWAT: Genetic and functional changes in mitochondria associated with aging. Fhjiiol Rrv. (1997) 77:425-464.
123. YU ÇA, YU L: Syntheses of biologically active ubiquinone derivatives. Biochemistry (1982) 21:4096-4101.
124. GILLIS JC, BENEFIELD P, MCTAVISH D: Idebenone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive disorders. Drugs Aging (1994) 5:133-152. • A review of one of the most promising anti-oxidams commonly given to mitochondrial patients.
125. IMADA I, FUJITA T, SUGIYAMA Y, OKAMOTO K, KOBAYASHI Y: Effects of idebenone and related compounds on respiratory activities of brain mitochondria and on lipid peroxidation of their membranes. Arch. GcrontoL Geriatr. (1989) 8:323-341.
126. TORII H, YOSHIDA K, KOBAYASHI T, TSUKAMOTO T, TANAYAMA S: Disposition of idebenone (CV-2619), a new cerebral metabolism improving agent, in rats and dogs.J. Pharmacobiodyn. (1985) 8:457-467.
127. LODIR, HART PE, RAJAGOPALAN B et al: Amioxidant treatment improves in vim cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann. NeuroL (2001) 49:590-596.
128. RUSTINP.VONKLEIST-RETZOWJC, CHANTREL-GROUSSARD K étal.: Effect of idebenone on cardiomyopathy in Friedreichs ataxia: a preliminary study. Lancet (1999) 354:477-479.
129. LERMAN-SAGIET, RUSTIN P, LEV D et al: Dramatic improvement in mitochondrial cardiomyopathy following treatment with idebenone.J. Inherit. Mctab. Dis. (2001) 24:28-34.
130. NAPOLITANO A, SALVETTIS, VISTA M et al: Long-term treatment with idebenone and riboflavin in a patient with MELAS. NeuroL Set. (2000) 21:5981-982.
131. WEYERG, BABEJ-DOLLE RM, HAULER D, HOFMANN S and HERRMANN WM: A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology (1997)36:73-82.
132. MUELLERGM, MCKENZIELR, HOMANIACS GE, WATKINS SC, ROBBINSPD.PAULHS: Complementation of defective leucine decarboxylation in fibroblasts from a maple syrup urine disease patient by retrovirusmediated gene transfer. Gene Therapy (1995) 2:461-468.
133. CHRZANOWSKA-LIGHTOWLERS ZMA, LIGHTOWLERS RN, TURNBULL DM: Gene therapy for mitochondrial DNA defects: is it possible? Gene Therapy (1995) 2:311-316. • A review outlining the difficulties facing mtDNA gene therapies.
134. MURPHY MP: Targeting bioactive compounds to mitochondria. Trends BiotechnoL (1997) 15:326-330. • An outline of the strategics that can be used to target molecules to mitochondria.
135. COLLOMBETJM.COUTELLEC: Towards gene therapy of mitochondrial disorders. MoL Med. Today (1998) 4:31-38.
136. KOLESNIKOVA OA, ENTELIS NS, MIREAU H, FOXTD, MARTIN TD, TARASSOVIA: Suppression of mutations in mitochondrial DNA by tRNAs imponed from the cytoplasm. Science (2000) 289:1931-1933.
137. CLARK K, AL E: Correction of a mitocohondrial DNA defect in human skeletal muscle. Nature Genet. (1997) 16:222-224.
138. TATVASSALO T, FU K, JOHNS T, ARNOLD D, KARPATI G, SHOUBRIDGE EA: Gene shifting: a novel therapy for mitochondrial myopathy. Hum. Mol. Genet. (1999) 8:1047-1052.
139. RUBENSTEINDS, THOMASMADC, SCHON EA, ZINAMAN MJ: Germ-line therapy to cure mitochondrial disease: protocol and ethics of in vitro ovum nuclear transplantation. Camb. QHealthc. Ethics (1995) 4:316-339.
140. SOHOL RS, WEINDRUCH R: Oxidative stress, caloric restriction and aging. Science (1996)273:59-63.
141. LEE C-K, KLOPP RG, WEINDRUCH R, PROLLA TA: Gene expression profile of aging and its retardation by caloric restriction. Science (1999) 285:1390-1393.
142. MURPHY MP, SMITH RAJ: Drug delivery to mitochondria: the key to mitochondrial medicine. Advanced Drug Deliv. Rev. (2000) 41:235-250.
143. CHEN LB: Mitochondrial membrane potential in living cells. Ann. Rev. CellBiol (1988)4:155-181.
144. LIBERMAN EA, TOPALIVP, TSOFINA LM, JASAITIS AA, SKULACHEV VP: Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature (1969) 222:1076-1078. •• The first demonstration of the uptake of lipophilic phosphonium cations by mitochondria.
145. AZZONE GF, PIETROBON D, ZORATTIM: Determination of the proton electrochemical gradient across biological membranes. Curr. Topics Bioenergetics (1984) 13:1-77.
146. BRAND MD: Measurement of mitochondrial protonmotive force. In: Bioenergetics - a practical approach. GC Brown, CE Cooper (Eds.), IRL, Oxford (1995):39-62.
147. RIDEOUT DC, CALOGEROPOULOU T, JAWORSKIJS, DAGNINO R, MCCARTHY MR: Phosphonium salts exhibiting selective anti-carcinoma activity in vitro. Anti-Cancer Drug Design (1989) 4:265-280.
148. RIDEOUT D: Self assembling drugs: a new approach to biochemical modulation in cancer chemotherapy. Cancer Invest. (1994) 12:189-202.
149. RIDEOUT D.BUSTAMANTE A, PATEL J: Mechanism of inhibition of FaDu hypopharyngeal carcinoma cell growth by tetraphenylphosphnium chloride. Int. J. Cancer (1994) 57:247-253.
150. MODICA-NAPOLITANOJS.APRILLE JR: Delocalized lipophilic cations selectively, target the mitochondria of carcinoma cells. Adv. DnigDeliv. Rev. (2001) 49:63-70.
151. BURNS RJ, SMITH RAJ, MURPHY MP: Synthesis and characterization of thiobutyltriphenvlphosphonium bromide, a novel thiol reagent targetted to the mitochondrial matrix. Arch. Biochem. Biophys. (1995) 322:60-68.
152. BURNS RJ, MURPHY MP: Labelling of mitochondrial proteins in living cells by the thiol probe thioburyltriphenylphosphonium bromide. Arch. Biochem. Biophys. (1997) 339:33-39.
153. SMITH RAJ, PORTEOUS CM, COULTER CV, MURPHY MP: Targeting an antioxidant to mitochondria. Ear. J. Biochem. (1999) 263:709-716. • • The first demonstration that ami-oxidants could be targeted to mitochondria within cells.
154. COULTER CV, KELSO GF, LIN T-K, SMITH RAJ, MURPHY MP: Mitochondrially targeted antioxidants and thiol reagents. Free Rod. Biol. Med. (2000) 28:1547-1554.
155. KELSO GF, PORTEOUS CM, COULTER CV et al.: Selective targeting of a rcdox-active ubiquinone to mitochondria within cells. J.Biol Chem. (2001) 276:4588-4596.
156. •• A demonstration that a ubiquinol analogue can be targeted to mitochondria within cells where it acts as an anti-oxidant and can be recycled by the respiratory chain.
157. MURATOVSKAA, LIGHTOWLERSRN, TAYLOR RW et al: Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease. Nucleic Acids Res. (2001) 29:1852-1863.
158. KAUPPINEN R: Proton electrochemical potential of the inner mitochondrial membrane in isolated perfused rat hearts, as measured by exogenous probes. Biochim. Biophys. Acta (1983) 72.5:131-137.
159. SRTVASTAVA PC, HAY HG, KNAPP FF: Effects of alkyl and aryl substitution on the myocardial specificity of radioiodinated phosphonium, arsonium and ammonium cations.J. Med. Chem. (1985) 28:901-904.
160. 11C-triphenylmethylphosphonium for the evaluation of membrane potential in the heart by positron-emission tomography. Eur. J. Nucl Med. (1986)11:478-483.
161. STEEN H, MAKING JG, MEIJER DK: Differential effects of metabolic inhibitors on cellular and mitochondrial uptake of organic cations in rat liver. Biochem. PharmacoL (1993) 45:809-818.
162. WAN B, DOUMEN C, DUSZYNSKIJ, SALAMA G, LANGUE KF: A method of determining electrical potential gradient across mitochondrial membrane in perfused rat hearts. Am. J. Physiol. (1993) 265:H445-H452.